Biotech
A Robot Arm Now Builds Cancer Cures 74% Cheaper — and Multiply Labs Just Raised $75 Million to Scale It
Multiply Labs raised a $75M Series B on Oct 6, 2026 to scale robots that make cell therapies up to 74% cheaper per dose.
Topic
Biotech
The latest Biotech news and analysis from Tech Arcade.
Startups
Varda Grows Drugs in Orbit, Parachutes Them Home — and Just Priced That at $1.6 Billion
Varda Space raised a $250M Series D at a $1.6B valuation to scale pharmaceutical manufacturing in orbit.
Biotech
The First Treatment for "Childhood Alzheimer's" Is One Shot — and a $3.95 Million Bill
The FDA just approved FAYUVI, the first-ever treatment for Sanfilippo syndrome type A: a one-time gene therapy from Ultragenyx priced at $3.95 million per patient.
Biotech
Half of These Lupus Patients Hit Remission on One Off-the-Shelf Dose
Adicet's off-the-shelf CAR-T put 54% of a small lupus trial into remission on a single dose. Then the stock dropped 22%.
Biotech
The Brain Chip That Doesn't Drill Just Raised $250 Million
Precision Neuroscience closed an oversubscribed $250M Series D at a ~$1B valuation, betting its surface brain implant beats drilling into tissue.
Biotech
The First Sanfilippo Drug Ever Just Landed — at $3.95 Million a Dose
Ultragenyx's Fayuvi is the first-ever treatment for Sanfilippo syndrome type A — a one-time gene therapy priced at $3.95 million.
Biotech
Basecamp Research Raised $140M to Teach AI the 99% of Biology Nobody Ever Sequenced
Basecamp Research raised a $140M Series C led by S32, with Anthropic and Nvidia backing an AI trained on DNA from over a million barely-studied species to design medicine from scratch.
Pharmatech
A Fatal Childhood Brain Disease Had Zero Treatments. The FDA Just Approved a $3.95 Million One.
The FDA approved Ultragenyx's Fayuvi, the first-ever treatment for Sanfilippo syndrome type A, a fatal childhood brain disease with zero prior options. The one-time gene therapy lists at $3.95 million.
AI
ByteDance Spun Its Drug Lab Into a $1.5 Billion Startup. It Hasn't Dosed a Single Patient.
ByteDance spun its in-house AI-for-science team into Anew Labs, which raised $290M at a $1.5B valuation with the TikTok owner keeping 56% — four drug programs, none yet in human trials.
Biotech
A Drug Just Beat Keytruda on Survival for the First Time — by 8.2 Months
Ivonescimab lived a median 30.8 months vs Keytruda's 22.6 in a head-to-head lung cancer trial — the first clear survival win over the world's best-selling drug.
Biotech
The Childhood Brain Cancer That Kills Every Patient Just Met a $116M CAR-T
BrainChild Bio raised $116M to run the pivotal trial for BCB-276, a CAR-T that pushed DIPG survival from ~11 to 19.8 months in a cancer that has beaten every drug for 50 years.
Biotech
Lilly Just Paid Up to $2.88 Billion for a Startup With Zero Approved Drugs
Eli Lilly is paying up to $2.88 billion for Merida Biosciences, a 16-month-old startup whose lead autoimmune drug is still in Phase 1.
Biotech
A Once-Daily Pill Nearly Doubled Pancreatic Cancer Survival. Wall Street Shrugged.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
Biotech
A Pill Just Doubled Survival in Pancreatic Cancer. The FDA Cleared It in About a Month — at $477,000 a Year.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Biotech
Ultragenyx's First Gene Therapy Costs $2.7 Million. It Buys GSDIa Patients Freedom From the Cornstarch Clock.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
Biotech
AusperBio Raised $120 Million on a Hepatitis B Drug That Cleared the Virus in 68% of a Small Trial
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
Biotech
Moderna and Merck's Cancer Vaccine Cleared Phase 3. The Stock Doubled Before Anyone Saw the Numbers.
Moderna and Merck's personalized mRNA cancer vaccine cleared Phase 3 in 1,137 melanoma patients — and Moderna's stock more than doubled before the full numbers were even released.
Biotech
Takeda Cracked Orexin. Its First-in-Class Narcolepsy Pill Could Do $2 Billion.
Takeda's Orzeyful is the first-in-class orexin agonist cleared to treat narcolepsy type 1 at its root cause — and Jefferies pegs peak sales near $2 billion.
Biotech
Ultragenyx Won Its First Gene Therapy Approval — and the Headline Number Is 31% Less Cornstarch
The FDA approved GENGLYCOS, Ultragenyx's first gene therapy and the first treatment for the root cause of glycogen storage disease type Ia. The headline result: 31% less daily cornstarch.
Biotech
Bristol Myers Just Launched a Whole New Class of Myeloma Drug — and Priced It at $29,500 a Cycle
Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.
Biotech
Jazz Just Paid $820 Million for an Epilepsy Drug Still Stuck in Phase 1 — and It's Meant for 2,500 People
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.
Biotech
Rejected Twice, Approved on the Third Try: The Tumor-Injected Virus That Just Cleared the FDA
After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.
Biotech
Moderna's mRNA Flu Shot Beat the Standard Jab by 27% — and the FDA Nearly Never Reviewed It
The FDA just approved mFlusiva, the first mRNA flu vaccine ever — 26.6% more effective than the standard shot in adults 50+, six months after the agency refused to review it.
AI
An AI Drug Company Just Committed $2.2 Billion — Without Discovering a Single Molecule
Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.